The level of resolution on the video was high-definition sharpness, and the foreboding shots taken by the camera guaranteed that it was both a sensation as well as its own catalyst for subsequent ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell therapy businesses, which will result in the loss of around 300 jobs or ...